Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -67.39% | -95.71% | -96.76% | -98.40% | -97.53% |
| Depreciation & Amortization | -- | 100.00% | -- | -97.50% | -93.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.59% | -95.49% | -97.48% | -98.34% | -97.37% |
| Operating Income | 70.59% | 95.49% | 97.48% | 98.34% | 97.37% |
| Income Before Tax | 44.00% | 95.52% | 93.75% | 95.72% | 96.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.00% | 95.52% | 93.75% | 95.72% | 96.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.00% | 95.52% | 93.75% | 95.72% | 96.25% |
| EBIT | 70.59% | 95.49% | 97.48% | 98.34% | 97.37% |
| EBITDA | -- | 96.53% | 109.26% | 102.24% | 97.53% |
| EPS Basic | 0.00% | 95.58% | 95.65% | 96.36% | 98.00% |
| Normalized Basic EPS | 100.00% | 95.16% | 93.33% | 97.06% | 96.77% |
| EPS Diluted | 0.00% | 95.58% | 95.65% | 96.36% | 98.00% |
| Normalized Diluted EPS | 100.00% | 95.16% | 93.33% | 97.06% | 96.77% |
| Average Basic Shares Outstanding | 0.00% | -0.06% | 2.98% | 6.22% | 41.43% |
| Average Diluted Shares Outstanding | 0.00% | -0.06% | 2.98% | 6.22% | 41.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |